These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 10895368)

  • 1. Birmingham vasculitis activity score, disease extent index and complement factor C3c reflect disease activity best in hepatitis C virus-associated cryoglobulinemic vasculitis.
    Lamprecht P; Moosig F; Gause A; Herlyn K; Gross WL
    Clin Exp Rheumatol; 2000; 18(3):319-25. PubMed ID: 10895368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological and clinical follow up of hepatitis C virus associated cryoglobulinaemic vasculitis.
    Lamprecht P; Moosig F; Gause A; Herlyn K; Csernok E; Hansen H; Gross WL
    Ann Rheum Dis; 2001 Apr; 60(4):385-90. PubMed ID: 11247870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hepatitis C virus-associated cryoglobulinemic vasculitis: A 20-year experience with treatment].
    Ignatova TM; Kozlovskaya LV; Gordovskaya NB; Chernova OA; Milovanova SY; Novikov PI; Nekrasova TP; Beketova TV; Mukhin NA
    Ter Arkh; 2017; 89(5):46-52. PubMed ID: 28631698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Cacoub P; Saadoun D; Limal N; Sene D; Lidove O; Piette JC
    Arthritis Rheum; 2005 Mar; 52(3):911-5. PubMed ID: 15751068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis.
    Comarmond C; Garrido M; Pol S; Desbois AC; Costopoulos M; Le Garff-Tavernier M; Si Ahmed SN; Alric L; Fontaine H; Bellier B; Maciejewski A; Rosenzwajg M; Klatzmann D; Musset L; Poynard T; Cacoub P; Saadoun D
    Gastroenterology; 2017 Jun; 152(8):2052-2062.e2. PubMed ID: 28274850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus-related cryoglobulinemic vasculitis treated with antiviral therapy.
    Landau DA; Scerra S; Sene D; Resche-Rigon M; Saadoun D; Cacoub P
    J Rheumatol; 2010 Mar; 37(3):615-21. PubMed ID: 20110523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis.
    Landau DA; Rosenzwajg M; Saadoun D; Trébeden-Negre H; Klatzmann D; Cacoub P
    Arthritis Rheum; 2008 Sep; 58(9):2897-907. PubMed ID: 18759287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study.
    Saadoun D; Resche-Rigon M; Thibault V; Piette JC; Cacoub P
    Arthritis Rheum; 2006 Nov; 54(11):3696-706. PubMed ID: 17075881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life in severe cryoglobulinaemic vasculitis and improvement after B-cell depleting therapy.
    Quartuccio L; Isola M; Masolini P; Scaini P; Zani R; Tavoni A; Pietrogrande M; Bombardieri S; De Vita S
    Clin Exp Rheumatol; 2013; 31(1 Suppl 75):S9-14. PubMed ID: 23044040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy.
    Mazzaro C; Carniello GS; Colle R; Doretto P; Mazzi G; Crovatto M; Santini GF; Tulissi P; Gregoretti M; Mazzoran L; Russo A; Silvestri F; Pozzato G
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):343-50. PubMed ID: 9476189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure.
    Bonacci M; Lens S; Mariño Z; Londoño MC; Rodriguez-Tajes S; Sánchez-Tapias JM; Ramos-Casals M; Hernández-Rodríguez J; Forns X
    Gastroenterology; 2018 Aug; 155(2):311-315.e6. PubMed ID: 29705529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hepatitis C virus-related cryoglobulinemic vasculitis with renal involvement: current possibilities of treatment].
    Gordovskaia NB; Kozlovskaia LV; Milovanova SIu; Ignatova TM; Korotchaeva IuV
    Ter Arkh; 2013; 85(6):78-84. PubMed ID: 23866603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement.
    Hu W; Liu C; Xie H; Chen H; Liu Z; Li L
    Nephrol Dial Transplant; 2008 Apr; 23(4):1307-12. PubMed ID: 18065810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study.
    Mazzaro C; Zorat F; Caizzi M; Donada C; Di Gennaro G; Maso LD; Carniello G; Virgolini L; Tirelli U; Pozzato G
    J Hepatol; 2005 May; 42(5):632-8. PubMed ID: 15826710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic sclerosis and cryoglobulinemia: our experience with overlapping syndrome of scleroderma and severe cryoglobulinemic vasculitis and review of the literature.
    Giuggioli D; Manfredi A; Colaci M; Manzini CU; Antonelli A; Ferri C
    Autoimmun Rev; 2013 Sep; 12(11):1058-63. PubMed ID: 23806565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of mixed cryoglobulinemia: a rheumatology perspective.
    De Vita S
    Clin Exp Rheumatol; 2011; 29(1 Suppl 64):S99-103. PubMed ID: 21586203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum concentrations of interleukin 1beta, CXCL10, and interferon-gamma in mixed cryoglobulinemia associated with hepatitis C infection.
    Antonelli A; Ferri C; Ferrari SM; Ghiri E; Marchi S; Sebastiani M; Fallahi P
    J Rheumatol; 2010 Jan; 37(1):91-7. PubMed ID: 19918044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis.
    De Vita S; Quartuccio L; Isola M; Mazzaro C; Scaini P; Lenzi M; Campanini M; Naclerio C; Tavoni A; Pietrogrande M; Ferri C; Mascia MT; Masolini P; Zabotti A; Maset M; Roccatello D; Zignego AL; Pioltelli P; Gabrielli A; Filippini D; Perrella O; Migliaresi S; Galli M; Bombardieri S; Monti G
    Arthritis Rheum; 2012 Mar; 64(3):843-53. PubMed ID: 22147661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current possibilities for treatment for hepatitis C virus-induced cryoglobulinemic vasculitis and B-cell lymphoma].
    Ignatova TM; Mukhin NA
    Ter Arkh; 2012; 84(11):81-8. PubMed ID: 23252255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis.
    Saadoun D; Resche Rigon M; Pol S; Thibault V; Blanc F; Pialoux G; Karras A; Bazin-Kara D; Cazorla C; Vittecoq D; Musset L; Peltier J; Decaux O; Ziza JM; Lambotte O; Cacoub P
    J Hepatol; 2015 Jan; 62(1):24-30. PubMed ID: 25135864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.